

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

DIVISION OF CORPORATION FINANCE

October 12, 2017

James Martin Chief Financial Officer Cocrystal Pharma, Inc. 1860 Montreal Road Tucker, GA 30084

> Re: Cocrystal Pharma, Inc. Information Statement on Schedule 14C Filed October 4, 2017 File No. 000-55158

Dear Mr. Martin:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence by the staff.

Division of Corporation Finance Office of Healthcare & Insurance

cc: Michael D. Harris, Esq. - Nason, Yeager, Gerson, White & Lioce, P.A.